Fundz

Fundz Deep Dive

Everything you need to win Orbis Medicines — in one platform.

Who to reach, what to say, and why now on Orbis Medicines — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Orbis Medicines — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Orbis Medicines and Vivtex Form Research & Exclusive Licensing Collaboration for Next-Generation Orally Dosable ‘nCycles'

Sep 17, 2024•over 1 year ago

Contract Type

partnership

CopenhagenBiotechnology

Description

Orbis Medicines and Vivtex have formed a research collaboration and option to an exclusive license. The collaboration will enable Orbis to utilize Vivtex’s GI-ORIS™ platform for gut permeability screening to evaluate the oral bioavailability of Orbis’ portfolio of next-generation macrocycle drugs called ‘nCycles’. This partnership aims for faster development of high-quality candidates for clinical entry and bringing a new generation of macrocycle drugs to patients.

Company Information

Company

Orbis Medicines

Location

Copenhagen, Capital Region Of Denmark, Denmark

About

Orbis Medicines is a biotechnology company focused on pioneering a new era for oral macrocycle drug discovery. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties, defined by the presence of a cyclic structure. Orbis’ nGen platform is designed to systematically explore the macrocycle chemical space using a highly automated chemistry platform and deliver oral macrocycle drug candidates – nCycles – suitable for both intra- and extracellular targets. Orbis’ programs are focused on high-value oral alternatives to blockbuster biologic drugs and targets challenging for established modalities.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Orbis Medicines's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.